Network of NASH PASS Clinical Trial Sites, Ready for Immediate Start

ProSciento has cultivated relationships with investigational sites that can contribute at-risk patients for inclusion in ProSciento’s NASH PASS program, where they will undergo phenotyping per the NASH PASS protocol and can be pre-screened for specific interventional study protocols. For NAFLD/NASH clinical trial enrollment, this means access to a large population of diagnosed, research-ready patients at pre-qualified sites ready for an expedited start. Moreover, patients screened and diagnosed via NASH PASS screening are reserved for NASH PASS-client studies, eliminating competing protocols within a site.